THE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5523Keywords:
Intranasal Esketamine; Esketamine Nasal Spray; Treatment-Resistant Depression; Major Depressive Disorder; Adjunctive TherapyAbstract
Introduction: Treatment-resistant depression (TRD) is a major public health and societal challenge, associated with persistent symptoms, functional impairment, and increased healthcare and economic burden. Intranasal esketamine has emerged as a rapid-acting adjunctive therapy with a distinct glutamatergic mechanism of action. This systematic review summarizes current evidence on its effectiveness and implementation-relevant outcomes in TRD.
Methods: A systematic literature review was conducted in accordance with PRISMA 2020. PubMed/MEDLINE and EMBASE were searched for English-language systematic reviews and meta-analyses published between 2010 and 2026 using database-specific but equivalent Boolean strategies combining intranasal esketamine terms with TRD terms. Titles/abstracts were screened and eligible records underwent full-text assessment. Five studies were included in qualitative synthesis. The last search was conducted on 5 March 2026.
Results: Meta-analytic evidence from randomized trials reported greater symptom improvement with intranasal esketamine versus control (MADRS SMD = −3.88; 95% CI −5.71 to −2.05) and higher response rates (RR = 1.99; 95% CI 1.28–3.10), alongside improvements in disability (SDS SMD = −3.01) and patient-reported symptoms (PHQ-9 SMD = −2.32). Adverse events were more frequent, including dizziness (RR = 3.55) and nausea (RR = 3.88). Real-world data showed substantial symptom reduction (Hedges’ g = −1.98) and higher remission likelihood at three months (OR = 5.1), with high overall adverse-event prevalence (82%) and dissociation commonly reported (49%).
Conclusions: Intranasal esketamine shows clinically relevant benefits in TRD with convergent trial and real-world signals, but requires supervised delivery and sustained follow-up. Further research should clarify long-term outcomes, clinical meaningfulness, and health-system cost-effectiveness.
References
Boudieu, L., Mennetrier, M., Llorca, P. M., & Samalin, L. (2023). The efficacy and safety of intranasal formulations of ketamine and esketamine for the treatment of major depressive disorder: A systematic review. Pharmaceutics, 15(12), 2773. https://doi.org/10.3390/pharmaceutics15122773
Sforzini, L., Worrell, C., Kose, M., Anderson, I. M., Aouizerate, B., Arolt, V., Bauer, M., Baune, B. T., Blier, P., Cleare, A. J., Cowen, P. J., Dinan, T. G., Fagiolini, A., Ferrier, I. N., Hegerl, U., Krystal, A. D., Leboyer, M., McAllister-Williams, R. H., McIntyre, R. S., . . . Pariante, C. M. (2022). A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Molecular Psychiatry, 27(3), 1286–1299. https://doi.org/10.1038/s41380-021-01381-x
Rush, A. J., Thase, M. E., & Dubé, S. (2003). Research issues in the study of difficult-to-treat depression. Biological Psychiatry, 53(8), 743–753. https://doi.org/10.1016/S0006-3223(03)00088-X
Dębowska, W., Więdłocha, M., Dębowska, M., Kownacka, Z., Marcinowicz, P., & Szulc, A. (2023). Transcranial magnetic stimulation and ketamine: Implications for combined treatment in depression. Frontiers in Neuroscience, 17, 1267647. https://doi.org/10.3389/fnins.2023.1267647
Bhavya, Shetty, S., & Sadasivam, B. (2025). A new era for esketamine in managing treatment-resistant depression: A systematic review of its use from adjunct to first-line therapy. Cureus, 17(9), e91829. https://doi.org/10.7759/cureus.91829
Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H. (2017). Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: A PET study in conscious monkeys. European Archives of Psychiatry and Clinical Neuroscience, 267(2), 173–176. https://doi.org/10.1007/s00406-016-0692-7
Ouyang, Y., & Li, J. (2025). Efficacy of esketamine nasal spray for treatment-resistant depression: A meta-analysis of randomized controlled studies. Medicine, 104(9), e41495. https://doi.org/10.1097/MD.0000000000041495
de Oliveira Lapa, C., Viola, T., Delfino, R., Dutra, L., Rubira, G., Rodrigues, R. J. K., Coral, S. C., Ramos-Quiroga, J. A., & Spanemberg, L. (2026). Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies. Journal of Affective Disorders, 401, 121257. https://doi.org/10.1016/j.jad.2026.121257
Capuzzi, E., Caldiroli, A., Capellazzi, M., Tagliabue, I., Marcatili, M., Colmegna, F., Clerici, M., Buoli, M., & Dakanalis, A. (2021). Long-term efficacy of intranasal esketamine in treatment-resistant major depression: A systematic review. International Journal of Molecular Sciences, 22(17), 9338. https://doi.org/10.3390/ijms22179338
Sapkota, A., Khurshid, H., Qureshi, I. A., Jahan, N., Went, T. R., Sultan, W., & Alfonso, M. (2021). Efficacy and safety of intranasal esketamine in treatment-resistant depression in adults: A systematic review. Cureus, 13(8), e17352. https://doi.org/10.7759/cureus.17352
Naudet, F., Pellen, C., Fodor, L. A., Gastaldon, C., Barbui, C., Turner, E. H., Le Pabic, E., & Cristea, I. A. (2025). Efficacy and safety of esketamine for “treatment resistant depression”: Registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. BMC Medicine, 23(1), 677. https://doi.org/10.1186/s12916-025-04435-x
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., & Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 75(2), 139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., Ravindran, A., Gaillard, R., Van den Ameele, H., Preskorn, S., Manji, H., & Drevets, W. C. (2019). Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 22(10), 616–630. https://doi.org/10.1093/ijnp/pyz039
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., & Drevets, W. C. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. American Journal of Psychiatry, 176(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Thase, M. E., Manji, H., & Drevets, W. C. (2020). Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression (TRANSFORM-3): A randomized, double-blind, active-controlled study. American Journal of Geriatric Psychiatry, 28(2), 121–141. https://doi.org/10.1016/j.jagp.2019.10.008
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., Manji, H., & Drevets, W. C. (2019). Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 76(9), 893–903. https://doi.org/10.1001/jamapsychiatry.2019.1189
Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., & CANMAT Depression Work Group. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Canadian Journal of Psychiatry, 69, 641–687. https://doi.org/10.1177/07067437241245384
National Institute for Health and Care Excellence. (2022). Esketamine nasal spray for treatment-resistant depression (Technology appraisal guidance TA854). https://www.nice.org.uk/guidance/ta854
McQuaid, J. R., Buelt, A., Capaldi, V., Fuller, M., Issa, F., Lang, A. E., Hoge, C., Oslin, D. W., Sall, J., Wiechers, I. R., & Williams, S. (2022). The management of major depressive disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline. Annals of Internal Medicine, 175(11), 1440–1451. https://doi.org/10.7326/M22-1603
Zhdanava, M., Pilon, D., Ghelerter, I., Chow, W., Joshi, K., Lefebvre, P., Sheehan, J. J., & Williamson, T. (2021). The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. Journal of Clinical Psychiatry, 82(2), 20m13699. https://doi.org/10.4088/JCP.20m13699
Ross, E. L., Zivin, K., Maixner, D. F., & Valenstein, M. (2020). Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatric Services, 71(10), 988–997. https://doi.org/10.1176/appi.ps.202000020
Institute for Clinical and Economic Review. (2019). Esketamine for the treatment of treatment-resistant depression: Final evidence report. https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf
Reif, A., Bitter, I., Buyze, J., Cebulla, K., Frey, R., Fu, D.-J., Ito, T., Kambarov, Y., Llorca, P.-M., Oliveira-Maia, A. J., Messer, T., Mulhern-Haughey, S., Rive, B., von Holt, C., Young, A. H., & Godinov, Y. (2023). Esketamine nasal spray versus quetiapine for treatment-resistant depression. New England Journal of Medicine, 389(14), 1298–1309. https://doi.org/10.1056/NEJMoa2304145
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., & Ferrari, A. J. (2022). Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry, 9(2), 137–150. https://doi.org/10.1016/S2215-0366(21)00395-3
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., & Ferrari, A. J. (2021). Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet, 398(10312), 1700–1712. https://doi.org/10.1016/S0140-6736(21)02143-7
Swainson, J., Thomas, R. K., Archer, S., Chokka, P., Frey, B. N., Jha, M. K., & Milev, R. (2021). The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the use of racemic ketamine in adults with major depressive disorder. Canadian Journal of Psychiatry, 66(2), 113–125. https://doi.org/10.1177/0706743720965142
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., Ly-Uson, J., Mansur, R. B., McAllister-Williams, R. H., Murrough, J. W., Nemeroff, C. B., Nierenberg, A. A., Rosenblat, J. D., Sanacora, G., Schatzberg, A. F., . . . Maj, M. (2023). Treatment-resistant depression: Definition, prevalence, detection, management, and investigational interventions. World Psychiatry, 22(3), 394–412. https://doi.org/10.1002/wps.21120
U.S. Food and Drug Administration. (2025). Spravato (esketamine) nasal spray, CIII: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s019lbl.pdf
Prasartpornsirichoke, J., Pityaratstian, N., Poolvoralaks, C., Sirinimnualkul, N., Ormtavesub, T., Hiranwattana, N., & Rungnirundorn, T. (2023). The prevalence and economic burden of treatment-resistant depression in Thailand. BMC Public Health, 23, 1541. https://doi.org/10.1186/s12889-023-16477-y
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014). Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach. Journal of Affective Disorders, 156, 1–7. https://doi.org/10.1016/j.jad.2013.10.043
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Wojciech Kotlarski, Klaudia Magdalena Kotlarska, Tomasz Stanisław Mainka, Emil Sergejuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
